标题
New drugs and regimens for tuberculosis
作者
关键词
-
出版物
RESPIROLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-06-19
DOI
10.1111/resp.13345
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong
- (2018) Kwok-Chiu Chang et al. EUROPEAN RESPIRATORY JOURNAL
- Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
- (2018) Simon Tiberi et al. LANCET INFECTIOUS DISEASES
- World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
- (2017) Dennis Falzon et al. EUROPEAN RESPIRATORY JOURNAL
- Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
- (2017) Ioana D. Olaru et al. EUROPEAN RESPIRATORY JOURNAL
- Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses
- (2017) Faiz Ahmad Khan et al. EUROPEAN RESPIRATORY JOURNAL
- Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens
- (2017) Liga Kuksa et al. EUROPEAN RESPIRATORY JOURNAL
- An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis
- (2017) Mayara Lisboa Bastos et al. EUROPEAN RESPIRATORY JOURNAL
- Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe
- (2017) Einar Heldal et al. EUROPEAN RESPIRATORY JOURNAL
- Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
- (2017) Jeffrey Hafkin et al. EUROPEAN RESPIRATORY JOURNAL
- Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance
- (2017) Armand Van Deun et al. EUROPEAN RESPIRATORY JOURNAL
- Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?
- (2017) Ilaria Motta et al. Expert Opinion on Drug Metabolism & Toxicology
- Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
- (2017) Giovanni Migliori et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India
- (2017) M. Mehra et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
- (2017) Keertan Dheda et al. RESPIROLOGY
- Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis
- (2017) Chi C. Leung et al. RESPIROLOGY
- Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro
- (2017) Shuo Zhang et al. Emerging Microbes & Infections
- Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis
- (2017) Giovanni Sotgiu et al. Lancet Respiratory Medicine
- The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
- (2017) Keertan Dheda et al. Lancet Respiratory Medicine
- Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients
- (2017) Sze Ling Chan et al. PLoS One
- Delamanid and Bedaquiline Resistance inMycobacterium tuberculosisAncestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee
- (2016) Harald Hoffmann et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study
- (2016) Ji-Hye Byun et al. CLINICAL DRUG INVESTIGATION
- Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea
- (2016) Hae-Young Park et al. CLINICAL THERAPEUTICS
- Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence
- (2016) Emanuele Pontali et al. EUROPEAN RESPIRATORY JOURNAL
- First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
- (2016) Marina Tadolini et al. EUROPEAN RESPIRATORY JOURNAL
- Evolving strategies for dose optimization of linezolid for treatment of tuberculosis
- (2016) E. Nuermberger INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Delamanid in the treatment of multidrug-resistant tuberculosis
- (2016) R. Gupta et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- WHO recommendations on shorter treatment of multidrug-resistant tuberculosis
- (2016) Giovanni Sotgiu et al. LANCET
- Bedaquiline plus delamanid for XDR tuberculosis
- (2016) Marie Lachâtre et al. LANCET INFECTIOUS DISEASES
- Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis
- (2016) Susanna Esposito et al. MEDICINE
- Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis
- (2016) A. Dorothee Heemskerk et al. NEW ENGLAND JOURNAL OF MEDICINE
- WHO strategies for the programmatic management of drug-resistant tuberculosis
- (2016) Alberto Matteelli et al. Expert Review of Respiratory Medicine
- Mutations in Genes for the F420Biosynthetic Pathway and a Nitroreductase Enzyme Are the Primary Resistance Determinants in SpontaneousIn Vitro-Selected PA-824-Resistant Mutants of Mycobacterium tuberculosis
- (2015) Hana L. Haver et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis
- (2015) N. Ndjeka et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon
- (2015) C. Kuaban et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis
- (2015) Rajesh Gupta et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015
- (2015) Y. Zhang et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
- (2015) Rodney Dawson et al. LANCET
- Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis
- (2015) Sandeep Tyagi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis
- (2015) Taeksun Song et al. EBioMedicine
- Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
- (2015) Lara J. Wolfson et al. PLoS One
- Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis
- (2014) R. C. Hartkoorn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Sputum Culture Conversion With Moxifloxacin-Containing Regimens in the Treatment of Patients With Newly Diagnosed Sputum-Positive Pulmonary Tuberculosis in South India
- (2014) B. V. Velayutham et al. CLINICAL INFECTIOUS DISEASES
- Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort
- (2014) L. Guglielmetti et al. CLINICAL INFECTIOUS DISEASES
- Smoking adversely affects treatment response, outcome and relapse in tuberculosis
- (2014) Chi C. Leung et al. EUROPEAN RESPIRATORY JOURNAL
- Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections
- (2014) S. Luque et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients
- (2014) K. J. M. Aung et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses
- (2014) A. Piubello et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
- (2014) Stephen H. Gillespie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies
- (2014) Thomas J Hwang et al. BMJ Open
- Assessment of Clofazimine Activity in a Second-Line Regimen for Tuberculosis in Mice
- (2013) Jacques H. Grosset et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Can Intermittent Dosing Optimize Prolonged Linezolid Treatment of Difficult Multidrug-Resistant Tuberculosis?
- (2013) Kwok-Chiu Chang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- WHO Group 5 Drugs and Difficult Multidrug-Resistant Tuberculosis: a Systematic Review with Cohort Analysis and Meta-Analysis
- (2013) Kwok-Chiu Chang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Systematic review of clofazimine for the treatment of drug-resistant tuberculosis [Review article]
- (2013) M. Gopal et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis Patients
- (2013) Mohideen S. Jawahar et al. PLoS One
- Pyrazinamide May Improve Fluoroquinolone-Based Treatment of Multidrug-Resistant Tuberculosis
- (2012) Kwok-Chiu Chang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis
- (2012) Ian M. Rosenthal et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis
- (2012) Giovanni Sotgiu et al. EUROPEAN RESPIRATORY JOURNAL
- Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
- (2012) Vija Skripconoka et al. EUROPEAN RESPIRATORY JOURNAL
- New drugs for the treatment of tuberculosis: hope and reality [State of the Art Series. New tools. Number 2 in the series]
- (2012) J. H. Grosset et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis
- (2012) Teesta Dey et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients
- (2012) W.-J. Koh et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
- (2012) Andreas H Diacon et al. LANCET
- Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial
- (2012) Rovina Ruslami et al. LANCET INFECTIOUS DISEASES
- Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
- (2012) Maria Tarcela Gler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
- (2012) Myungsun Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients
- (2012) Shama D. Ahuja et al. PLOS MEDICINE
- ‘ZS-MDR-TB’ versus ‘ZR-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility
- (2012) Ying Zhang et al. Emerging Microbes & Infections
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
- (2010) Armand Van Deun et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
- (2010) José A Caminero et al. LANCET INFECTIOUS DISEASES
- Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture Conversion
- (2009) John L. Johnson et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Efficacy of a 6-month versus 9-month Intermittent Treatment Regimen in HIV-infected Patients with Tuberculosis
- (2009) Soumya Swaminathan et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
- (2009) Marcus B Conde et al. LANCET
- Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
- (2008) E. Nuermberger et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
- (2008) R. Singh et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now